A database of FDA approved therapeutic peptides and proteins
ID1799 | ThPPIDTh1193 | NameTuroctocog alfa | Peptide SequenceNA Full view | Length0 | Functional ClassificationIa | DiseaseHematological Disorders | BrandZonovate | CompanyNovo Nordisk Canada Inc | Physical Appearancesterile, non-pyrogenic, white or slightly yellow Powder | Route of AdministartionIntravenous | CategoryNA | TargetNA |
ID1801 | ThPPIDTh1195 | NameSimoctocog Alfa | Peptide SequenceNA Full view | Length0 | Functional ClassificationIa | DiseaseHematological Disorders | BrandNuwiq | CompanyOctapharma Pharmazeutika Produktionsges M B H | Physical AppearancePowder and solvent for Solution | Route of AdministartionIntravenous infusion | CategoryAntihaemorrhagics: blood coagulation factor VIII | TargetNA |
ID1802 | ThPPIDTh1196 | NameSiltuximab | Peptide SequenceHeavy Chain Sequence Full view | Length708 | Functional ClassificationIIa | DiseaseImmunological Disorders | BrandSylvant | CompanyJanssen Inc | Physical AppearanceLyophilized Powder | Route of AdministartionIntravenous infusion | CategoryAntineoplastic and Immunomodulating Agents, Immunosuppressive Agents | TargetInterleukin-6 |
ID1809 | ThPPIDTh1200 | NameProthrombin complex concentrate | Peptide SequenceNA Full view | Length0 | Functional ClassificationIa | DiseaseHematological Disorders | BrandOctaplex | CompanyOctapharma | Physical AppearancePowder and solvent for Solution | Route of AdministartionIntravenous | CategoryNA | TargetNA |
ID1811 | ThPPIDTh1202 | NamePembrolizumab | Peptide SequenceHeavy Chain Sequence Full view | Length711 | Functional ClassificationIIIc | DiseaseCancer | BrandKeytruda | CompanyMerck Sharp & Dohme Corp. | Physical AppearanceLyophilized Powder | Route of AdministartionIntravenous infusion | CategoryAntineoplastic and Immunomodulating Agents | TargetProgrammed cell death protein 1 |
ID1817 | ThPPIDTh1208 | NameMetreleptin | Peptide SequenceMVPIQKVQDDTKTLIKTIVT Full view | Length147 | Functional ClassificationIb | DiseaseAdjunct therapy | BrandMyalept | CompanyAmylin Pharmaceuticals, LLC | Physical AppearanceLyophilized Powder for Solution | Route of AdministartionSubcutaneous | Category | TargetLeptin receptor |
ID1819 | ThPPIDTh1210 | NameMepolizumab | Peptide SequenceNA Full view | Length0 | Functional ClassificationIb | DiseaseRespiratory Disorder | BrandNucala | CompanyGlaxosmithkline Inc | Physical AppearanceLyophilized Powder | Route of AdministartionSubcutaneous | CategoryAntineoplastic and Immunomodulating Agents, Immunosuppressive Agents, Interleukin Inhibitors | TargetInterleukin-5 |
ID1831 | ThPPIDTh1221 | NameC1 Esterase Inhibitor (Recombinant) | Peptide SequenceNA Full view | Length0 | Functional ClassificationIIa | DiseaseCardiac Disorders | BrandRuconest | CompanyTjoapack Netherlands Bv | Physical AppearancePowder and liquid for solution | Route of AdministartionIntravenous | CategoryBlood and Blood Forming Organs | TargetComplement C1r subcomponent, Complement C1s subcomponent, Plasma kallikrein, Coagulation factor XII, Prothrombin, Coagulation factor XI, Tissue-type plasminogen activator |
ID1832 | ThPPIDTh1222 | NameCanakinumab | Peptide SequenceH-GAMMA-1 Chain: QVQ Full view | Length842 | Functional ClassificationIIa | DiseaseImmunological Disorders | BrandIlaris | CompanyNovartis | Physical AppearanceLyphilized powder | Route of AdministartionSubcutaneous | CategoryAntineoplastic and Immunomodulating Agents | TargetInterleukin-1 beta |
ID1835 | ThPPIDTh1224 | NameChorionic Gonadotropin (Recombinant) | Peptide SequenceAlpha chain : APDVQD Full view | Length237 | Functional ClassificationIa | DiseaseHormonal Disorders | BrandOvitrelle | CompanyMerck Serono Europe Limited | Physical Appearancepowder and solvent to be made up into a solution | Route of AdministartionSubcutaneous | CategoryHormones | TargetLutropin-choriogonadotropic hormone receptor, Follicle-stimulating hormone receptor |
ID1836 | ThPPIDTh1225 | NameCoagulation factor X human | Peptide SequenceNA Full view | Length0 | Functional ClassificationIb | DiseaseHematological Disorders | BrandCoagadex | CompanyNA | Physical Appearancepowder and solvent used to make a solution | Route of AdministartionIntravenous | CategoryBlood Coagulation Factors | TargetNA |
ID1838 | ThPPIDTh1227 | NameEfmoroctocog alfa | Peptide SequenceNA Full view | Length0 | Functional ClassificationIb | DiseaseHematological Disorders | BrandELOCTA | CompanyNA | Physical AppearancePowder and solvent for solution for injection | Route of AdministartionIntravenous | CategoryAntihemophilic Factor | TargetNA |
ID1839 | ThPPIDTh1228 | NameFactor IX Complex (Human) | Peptide SequenceNA Full view | Length0 | Functional ClassificationIb | DiseaseHematological Disorders | BrandAlphaNine SD or Mononine | Company | Physical AppearancePowder and solvent for solution for injection | Route of AdministartionIntravenous | CategoryAntihemophilic agent | TargetNA |
ID1842 | ThPPIDTh1230 | NameHuman Varicella-Zoster Immune Globulin | Peptide SequenceNA Full view | Length0 | Functional ClassificationIIIa | DiseaseInfectious Disease | BrandVARIZIG | CompanyNA | Physical Appearancelyophilized powder for solution | Route of AdministartionIntramuscular | CategoryAntibody | Targetvaricella zoster virus |
ID1846 | ThPPIDTh1234 | NameProtamine sulfate | Peptide SequenceNA Full view | Length0 | Functional ClassificationIb | DiseaseHematological Disorders | BrandProtamine Sulfate Injection, USP | CompanyOmega Laboratories Ltd | Physical Appearanceoff-white amorphous or crystalline powder | Route of AdministartionIntravenous | CategoryHeparin Antagonists, Hematologic Agents | TargetNA |
ID1849 | ThPPIDTh1237 | NameSomatropin recombinant | Peptide SequenceFPTIPLSRLFDNAMLRAHRL Full view | Length191 | Functional ClassificationIb | DiseaseHormonal Disorders | BrandBioTropin | CompanyBiotech General | Physical AppearancePowder and Solvent for Solution | Route of AdministartionSubcutaneous | CategoryHormones, Hormone Substitutes, and Hormone Antagonists | TargetGrowth hormone receptor, Prolactin receptor |
ID1851 | ThPPIDTh1238 | NameSusoctocog alfa | Peptide SequenceAIRRYYLGAVELSWDYRQSE Full view | Length1448 | Functional ClassificationIb | DiseaseHematological Disorders | BrandObizur | CompanyNA | Physical AppearancePowder and solvent for solution for injection. | Route of AdministartionIntravenous | CategoryBlood coagulation factors, Antihaemorrhagics | Targetvon Willebrand factor |
ID1852 | ThPPIDTh1239 | NameThrombomodulin Alfa | Peptide SequenceNA Full view | Length0 | Functional ClassificationIb | DiseaseHematological Disorders | BrandRecomodulin (in Japan only) | CompanyAsahi Kasei Pharma Corp | Physical Appearancelyophilized powder for solution | Route of AdministartionIntravenous | CategoryAnticoagulant agent, Antiplatelet agent | TargetProthrombin, Coagulation factor V |